Table 1.
Clinical and epidemiological characteristics of all HIV/HCV coinfected patients stratified by PPARγ2 genotype
| PPARγ2 polymorphism | ||||
|---|---|---|---|---|
| All patients (n = 257) | CC (n = 223) | CG/GG (n = 34) | p-value | |
| Gender (male) | 191 (74.3%) | 165 (74.0%) | 26 (76.5%) | 0.758 |
| Age (years) | 40.9 (37.9; 44.7) | 41.0 (37.9; 44.7) | 40.1 (36.0; 44.7) | 0.675 |
| BMI (kg/m2) | 22.5 (20.9; 24.7) | 22.5 (20.9; 24.7) | 22.6 (20.7; 24.3) | 0.875 |
| BMI ≥25 kg/m2 | 60 (23.4%) | 54 (23.9%) | 7 (20.6%) | 0.674 |
| HIV acquired by IVDU | 219 (85_.2%) | 191 (85.7%) | 28 (82.4%) | 0.785 |
| Years since HCV infection | 21.3 (16.6; 24.4) | 21.6 (16.7; 24.6) | 18.5 (16.1; 23.3) | 0.149 |
| Prior AIDS | 74 (28.8%) | 64 (28.7%) | 10 (29.4%) | 0.973 |
| cART | 215 (83.7%) | 186 (83.4%) | 29 (85.3%) | 0.831 |
| Time on cART (years) | 4.8 (2.9; 7.8) | 4.7 (2.7; 7.7) | 4.9 (3.3; 8.7) | 0.490 |
| Current cART protocols | ||||
| Any NRTIs + any PI | 62 (24.1%) | 51 (22.9%) | 11 (32.4%) | 0.229 |
| Any NRTIs + PI + NNRTI | 3 (1.2%) | 2 (0.9%) | 1 (2.9%) | 0.301 |
| Any NRTIs + any NNRTI | 130 (50.6%) | 114 (51.1%) | 16 (47.1%) | 0.659 |
| Only NRTIs | 20 (7.8%) | 19 (8.5%) | 1 (2.9%) | 0.258 |
| Specific antiretroviral drugs | ||||
| Zidovudine | 71 (7.6%) | 63 (28.8%) | 8 (23.5%) | 0.566 |
| Stavudine | 66 (25.7%) | 55 (25.4%) | 11 (32.4%) | 0.339 |
| Didanosine | 41 (16.0%) | 35 (15.7%) | 6 (17.6%) | 0.772 |
| Tenofovir | 70 (27.2%) | 59 (26.5%) | 11 (32.4%) | 0.472 |
| Abacavir | 43 (16.7%) | 41 (18.4%) | 2 (5.9%) | 0.069 |
| Efavirenz | 76 (29.6%) | 72 (32.3%) | 4 (11.8%) | 0.015 |
| Ritonavir | 47 (18.3%) | 38 (17.0%) | 9 (26.5%) | 0.185 |
| HIV markers | ||||
| Nadir CD4+ T-cells (cells/μL) | 208 (93; 314.5) | 195 (92.5; 306) | 257 (145; 364) | 0.176 |
| CD4+ T cells/μL | 467 (341.7; 670.7) | 467 (340; 660) | 471 (368; 690) | 0.678 |
| HIV-RNA <50 copies/mL | 76.6% (196/256) | 77.5% (172/222) | 70.6% (24/34) | 0.377 |
| HCV markers | ||||
| HCV-genotype 1/4 | 72.7% (181/249) | 72.1% (155/215) | 76.5% (26/34) | 0.594 |
| HCV-RNA ≥500,000 UI/ml | 75.6% (186/246) | 74.5% (158/212) | 82.4% (28/34) | 0.324 |
| Significant fibrosis (F ≥ 2) | 47.8% (99/207) | 46.7% (85/182) | 56.0% (14/25) | 0.383 |
Categorical variables are expressed in percentage (absolute count). Continuous variables are expressed in median (percentile 25; percentile 75). P-values were estimated with nonparametric Mann–Whitney U test for continuous variable and Chi-square test for categorical variable.
Abbreviations: AIDS acquired immunodeficiency syndrome, BMI body mass index, cART combination antiretroviral therapy, HCV hepatitis C virus, HCV-RNA HCV plasma viral load, HIV human immunodeficiency virus, HIV-RNA HIV plasma viral load, IVDU intravenous drug users, NNRTI no nucleoside analog reverse-transcriptase inhibitors, NRTI nucleoside analog reverse-transcriptase inhibitors, PI protease inhibitors.